BR0213581A - Uso de um inibidor de recaptação de norepinefrina seletivo - Google Patents

Uso de um inibidor de recaptação de norepinefrina seletivo

Info

Publication number
BR0213581A
BR0213581A BR0213581-7A BR0213581A BR0213581A BR 0213581 A BR0213581 A BR 0213581A BR 0213581 A BR0213581 A BR 0213581A BR 0213581 A BR0213581 A BR 0213581A
Authority
BR
Brazil
Prior art keywords
norepinephrine reuptake
reuptake inhibitor
selective norepinephrine
selective
cognitive impairment
Prior art date
Application number
BR0213581-7A
Other languages
English (en)
Inventor
Franklin Porter Bymaster
Donald Richard Gehlert
David Lee Mckinzie
Charles Renkin Yang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0213581A publication Critical patent/BR0213581A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"USO DE UM INIBIDOR DE RECAPTAçãO DE NOREPINEFERINA SELETIVO". Os inibidores de recaptação de norepinefrina seletivos, particularmente atomoxetina, reboxetina e fenoxifenil propilaminas substituídas por 2-alquiltio, são usados para o tratamento de insuficiência cognitiva, incluindo insuficiência cognitiva devido à demência, delírio e esquizofrenia.
BR0213581-7A 2001-12-11 2002-11-27 Uso de um inibidor de recaptação de norepinefrina seletivo BR0213581A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
PCT/US2002/036132 WO2003049724A1 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Publications (1)

Publication Number Publication Date
BR0213581A true BR0213581A (pt) 2004-08-24

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213581-7A BR0213581A (pt) 2001-12-11 2002-11-27 Uso de um inibidor de recaptação de norepinefrina seletivo

Country Status (26)

Country Link
US (1) US20050009925A1 (pt)
EP (1) EP1458368B1 (pt)
JP (1) JP2005517647A (pt)
KR (1) KR20040066895A (pt)
CN (1) CN1713900A (pt)
AU (1) AU2002352625A1 (pt)
BR (1) BR0213581A (pt)
CA (1) CA2467802A1 (pt)
CO (1) CO5590907A2 (pt)
CZ (1) CZ2004709A3 (pt)
DE (1) DE60223718T2 (pt)
EA (1) EA200400793A1 (pt)
EC (1) ECSP045145A (pt)
ES (1) ES2295435T3 (pt)
HR (1) HRPK20040528B3 (pt)
HU (1) HUP0402619A3 (pt)
IL (1) IL161989A0 (pt)
MX (1) MXPA04005716A (pt)
MY (1) MY136367A (pt)
NO (1) NO20042904L (pt)
NZ (1) NZ532065A (pt)
PL (1) PL369311A1 (pt)
SK (1) SK2442004A3 (pt)
TW (1) TW200300672A (pt)
WO (1) WO2003049724A1 (pt)
ZA (1) ZA200404274B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1530476A1 (en) * 2002-08-14 2005-05-18 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of hot flashes
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
EP1660064A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
CN1889940A (zh) * 2003-12-12 2007-01-03 伊莱利利公司 热潮红、冲动控制障碍和全身性医学病症引起的人格变化的治疗
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317730A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Treatment for menopausal and perimenopausal vasomotor symptons
TW201107485A (en) * 2009-07-31 2011-03-01 Univ Nat Taiwan Treating negative symptoms of schizophrenia associated with defective neuregulin 1 (NRG1)
WO2013051266A1 (ja) * 2011-10-03 2013-04-11 独立行政法人国立長寿医療研究センター タウ凝集阻害剤
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
PT1632234E (pt) * 1999-07-01 2007-07-09 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica
GEP20043160B (en) * 1999-10-13 2004-01-26 Pfizer Products Inc Us Biaryl Ether Derivatives, Pharmaceutical Compositions Containing Them and Their Use as Monoamine Reuptake Inhibitors
AU2002243451A1 (en) * 2001-01-02 2002-07-16 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory
AU2002232470B2 (en) * 2001-01-02 2005-11-03 Pharmacia & Upjohn Company Llc New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents

Also Published As

Publication number Publication date
CZ2004709A3 (cs) 2004-10-13
PL369311A1 (en) 2005-04-18
DE60223718T2 (de) 2008-10-30
CN1713900A (zh) 2005-12-28
EP1458368A1 (en) 2004-09-22
HRPK20040528B3 (en) 2006-03-31
MXPA04005716A (es) 2004-12-06
DE60223718D1 (de) 2008-01-03
ECSP045145A (es) 2004-07-23
WO2003049724A1 (en) 2003-06-19
NZ532065A (en) 2007-03-30
SK2442004A3 (en) 2004-12-01
ES2295435T3 (es) 2008-04-16
US20050009925A1 (en) 2005-01-13
JP2005517647A (ja) 2005-06-16
HRP20040528A2 (en) 2004-10-31
KR20040066895A (ko) 2004-07-27
CO5590907A2 (es) 2005-12-30
IL161989A0 (en) 2005-11-20
AU2002352625A1 (en) 2003-06-23
EP1458368B1 (en) 2007-11-21
EA200400793A1 (ru) 2004-10-28
HUP0402619A2 (hu) 2005-03-29
ZA200404274B (en) 2005-09-13
HUP0402619A3 (en) 2008-04-28
TW200300672A (en) 2003-06-16
NO20042904L (no) 2004-09-07
MY136367A (en) 2008-09-30
CA2467802A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
AR032086A1 (es) Combinaciones de farmacos
ECSP17046065A (es) Formas cristalinas de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenolhidrocloruro (solicitud divisional)
BR0213581A (pt) Uso de um inibidor de recaptação de norepinefrina seletivo
BR0113669A (pt) Inibidores da desacetilase
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
UY28348A1 (es) Compuestos novedosos
BR0317715A (pt) Composições e processos de uso de collajolie
AR026163A1 (es) Utilizacion de retigabina para el tratamiento de dolores neuropaticos
BRPI0212733B8 (pt) composição farmacêutica compreendendo composto inibidor da recaptação de serotonina, e, uso do mesmo
BR0312785A (pt) Tratamento de desordens relacionadas a tnf(alfa)
PT1259512E (pt) Compostos de pteridin para o tratamento da psoriase
PT1328269E (pt) Associacao de um antagonista do receptor cb1 e de sibutramina composicoes farmaceuticas que os contem e sua utilizacao para o tratamento da obesidade
RS20050392A (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor
BRPI0312649A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
AR036288A1 (es) Composicion de limpieza mejorada
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação
HK1077755A1 (en) Use of a paralpha agonist and metformin for the treatment of obesity ppar-alpha
BR0114903A (pt) 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação
BR0210650A (pt) Tablete, e, uso do mesmo
AR047553A1 (es) La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
EE200300547A (et) Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks
BRPI0506631B8 (pt) combinações, composição farmacêutica e usos das combinações
BR0115301A (pt) Uso de um inibidor seletivo da recaptação de norepinefrina
HRP20031057B1 (hr) Tableta koja sadrži cetirizin i pseudoefedrin
BRPI0416157A (pt) composição farmacêutica contendo um agonista de adrenoceptor beta-3 e um antagonista alfa e/ou um inibidor de 5-alfa redutase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.